FDA Clears Masimo's Root With LiDCO for Oxygen Delivery

FDA cleared Masimo Root with LiDCO and the Masimo LiDCO sensor on 25 August 2026, a 510(k) that lets clinicians watch oxygen delivery — the rate oxygen actually reaches tissue — move continuously on one monitor, instead of piecing it together from a cardiac-output number, an intermittent lab hemoglobin value, and a separate pulse oximeter reading.

Why oxygen delivery, and why now

Oxygen delivery is the product of cardiac output and arterial oxygen content, and arterial oxygen content is driven overwhelmingly by hemoglobin concentration and oxygen saturation. Clinicians in critical care and high-risk surgery have long tracked pieces of that equation separately: a pulse oximeter for saturation, continuously; a hemodynamic monitor for cardiac output, continuously; and hemoglobin from a blood gas analyzer or lab draw, intermittently — often only once or twice a shift. A DO₂ number calculated from a stale hemoglobin value can miss a real deterioration in a patient who is bleeding or diluting; Masimo's pitch is that stitching a continuous, noninvasive hemoglobin sensor into the same calculation removes the weakest, slowest-updating input in that chain.

Three technologies, one platform

Root is Masimo's modular bedside patient-monitoring platform, built to host interchangeable measurement boards rather than a single fixed sensor set. LiDCO's contribution is pulse-contour analysis of the arterial waveform to estimate cardiac output and stroke volume beat to beat, a technique LiDCO had sold as a standalone monitor for two decades before Masimo's 2021 acquisition folded it into Root as a plug-in module. SpHb is Masimo's own noninvasive hemoglobin measurement, derived from multi-wavelength pulse co-oximetry rather than a blood draw, and SET is the company's long-standing pulse oximetry signal-processing technology. This clearance is the first to formally combine all three into a single cleared continuous-DO₂ indication, rather than leaving clinicians to read the three parameters separately and calculate DO₂ by hand.

What is not yet public

Masimo's announcement does not disclose the FDA 510(k) submission number, so the clearance cannot yet be independently cross-checked against FDA's public 510(k) database, which typically lags a clearance announcement by days to weeks before the record posts. The company also has not published a specific predicate device comparison or performance-testing summary beyond describing the combined measurement as building on already-cleared component technologies. Regulatory News will update this story if FDA's database entry surfaces additional detail once indexed.